Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC with Portal Vein Invasion: a Randomized Trial
Compare the efficacy and safety of camrelizumab, apatinib plus FOLFOX-HAIC and camrelizumab plus apatinib in hepatocellular carcinoma with portal vein invasion.
Hepatocellular Carcinoma
PROCEDURE: FOLFOX-HAIC|DRUG: Camrelizumab|DRUG: Apatinib
Overall survival, the The date of randomization to death from any cause, 2 months
Progression-free survival, The date from randomization until progression according to RECIST 1.1 or death. from any cause, 2 months|Time to progression, The time from randomization until first evidence of disease progression., 2 months|Time to response, The time from initiating treatment to achieve complete or partial response according to RECIST 1.1, 2 months|Duration of response, The time from randomization to disease progression or death in patients who achieve complete or partial response according to RECIST 1.1, 2 months|Objective response rate, The proportion of patients with the best response of complete response or partial response according to RECIST 1.1, 2 months|Disease control rate, The proportion of patients with the best response of complete response, partial response and stable disease according to RECIST 1.1, 2 months
Compare the efficacy and safety of camrelizumab, apatinib plus FOLFOX-HAIC and camrelizumab plus apatinib in hepatocellular carcinoma with portal vein invasion.